The active ingredient of Elmiron (pentosan polysulfate sodium) is a semi-synthetic, heparin-like macromolecular carbohydrate derivative, which is chemically and structurally similar to glycosaminoglycans. This medication is primarily used to relieve bladder pain or discomfort associated with interstitial cystitis.

How to Use Elmiron (Pentosan Polysulfate Sodium)

Standard Dosing Regimen

The recommended dosage is 300 mg per day, administered as one 100 mg capsule taken orally three times daily.

The capsules should be white, opaque hard gelatin capsules imprinted with the marking "BNP7600".

Specific Administration Requirements

Capsules should be taken with water at least 1 hour before meals or 2 hours after meals.

The effect of food on the absorption of pentosan polysulfate sodium is not yet clear; therefore, strict adherence to this administration timing is recommended.

Handling Missed Doses

If a dose is missed or vomiting occurs after taking the medication, resume the next scheduled dose. Do not take an additional dose to make up for the missed one.

Dosage Adjustment of Elmiron (Pentosan Polysulfate Sodium)

Treatment Duration and Efficacy Evaluation

Patients should undergo re-evaluation 3 months after starting Elmiron treatment.

If no improvement is observed and no restrictive adverse events occur, treatment may be continued for an additional 3 months.

For patients with no pain improvement within 6 months, the clinical value and risks of continuing treatment remain unclear.

Dosage Management Based on Adverse Reactions

When patients experience specific adverse reactions, treatment strategies should be adjusted according to the severity of the reactions.

Clinical data show that long-term use of Elmiron may increase the risk of retinal pigment changes. Most cases occur after 3 or more years of use, but there are also reports of cases occurring with shorter durations of use.

Medication for Special Populations of Elmiron (Pentosan Polysulfate Sodium)

Patients with Hepatic Impairment

Elmiron has not been studied in patients with hepatic insufficiency.

Since there is evidence that the liver contributes to the elimination of Elmiron, hepatic impairment may affect the pharmacokinetics of Elmiron.

Caution should be exercised when using Elmiron in this patient population.

Lactating Women

It is currently unknown whether this medication is excreted in human milk. Since many drugs are excreted in human milk, caution should be exercised when administering Elmiron to lactating women.

Pediatric Patients

The efficacy of Elmiron in pediatric patients under 16 years of age has not been established.